Latest Digestion News
FRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.
These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia buildup can lead to coma, brain damage or death, the FDA said Friday in a news release.
Ravicti is marketed by Hyperion Therapeutics, based in South San Francisco, Calif.
-- Scott Roberts
Health Solutions From Our Sponsors